Cargando…

Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome

BACKGROUND: Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic and potentially life-threatening disease process, which may occur in healthy young women undergoing controlled ovarian hyperstimulation for assisted reproduction. As the treatment is largely empirical, prevention forms the mainsta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naredi, Nikita, Karunakaran, Sandeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963308/ https://www.ncbi.nlm.nih.gov/pubmed/24672164 http://dx.doi.org/10.4103/0974-1208.126293

Ejemplares similares

The Effectiveness of Cabergoline for the Prevention of Ovarian Hyperstimulation Syndrome
por: Hosseini, Marzieh Agha, et al.
Publicado: (2011)

GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial
por: Fouda, Usama M., et al.
Publicado: (2016)

Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study
por: Torabizadeh, Aalie, et al.
Publicado: (2013)

Does the timing of cabergoline administration impact rates of ovarian hyperstimulation syndrome?
por: Rubenfeld, Eryn Sara, et al.
Publicado: (2021)

High Dose Cabergoline in Management of Bilateral Ovarian Hyperstimulation Syndrome: A Case Report
por: Manalai, Gulparkha, et al.
Publicado: (2021)

Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection
por: Taheripanah, Robabeh, et al.
Publicado: (2018)

Evaluation of intravenous hydroxylethyl starch, intravenous albumin 20%, and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction
por: Ghahiri, Ataollah, et al.
Publicado: (2015)

Kallistatin prevents ovarian hyperstimulation syndrome by regulating vascular leakage
por: Huang, Jianfang, et al.
Publicado: (2022)

Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study
por: Kılıç, Niyazi, et al.
Publicado: (2015)

Prevention of Ovarian Hyperstimulation Syndrome: A Review
por: Smith, Vinayak, et al.
Publicado: (2015)

Ovarian hyperstimulation syndrome
por: Kumar, Pratap, et al.
Publicado: (2011)

Ovarian and intellectual hyperstimulation
por: Quaas, Alexander M.
Publicado: (2021)

Large-Volume Paracentesis, up to 27 L, With Adjuvant Vaginal Cabergoline in the Case of Severe Ovarian Hyperstimulation Syndrome with Successful Pregnancy Outcome: A Case Report
por: Agarwal, Nupur, et al.
Publicado: (2017)

Stimulation of Adrenal Chromaffin Cell Proliferation by Hypercalcemia Induced by Intravenous Infusion of Calcium Gluconate in Rats
por: Isobe, Kaori, et al.
Publicado: (2012)

GnRH Analogues in the Prevention of Ovarian Hyperstimulation Syndrome
por: Alama, Pilar, et al.
Publicado: (2013)

The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome
por: Chappell, Neil, et al.
Publicado: (2017)

Association of -460C/T and +405 G/C polymorphisms of vascular endothelial growth factor gene and susceptibility to ovarian hyperstimulation syndrome
por: Ghasemi, Nasrin, et al.
Publicado: (2017)

A modified GnRH antagonist method in combination with letrozole, cabergoline, and GnRH antagonist for PCOS: Safe and effective ovarian stimulation to treat PCOS and prevent OHSS
por: Yanagihara, Yasuho, et al.
Publicado: (2021)

The effect of calcium gluconate in the treatment of hyperkalemia
por: Celebi Yamanoglu, Nalan Gokce, et al.
Publicado: (2022)

Comparison of bromocriptine and hydroxyethyl starch in the prevention of ovarian hyperstimulation syndrome
por: Zhang, Qiaoli, et al.
Publicado: (2022)

Calcium gluconate: IM calcium deposition: case report
Publicado: (2021)

Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome
por: O’Brien, Travis J, et al.
Publicado: (2014)

Microvascular density and vascular endothelial growth factor and osteopontin expression during the implantation window in a controlled ovarian hyperstimulation rat model
por: GONG, XIN, et al.
Publicado: (2015)

Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis
por: Mahajan, Nalini, et al.
Publicado: (2015)

Ovarian Hyperstimulation Syndrome, the Master of Disguise?
por: Ironside, Emily Charlotte, et al.
Publicado: (2015)

Chemical Cardioversion of Atrial Fibrillation with Calcium Gluconate
por: Serhat, A, et al.
Publicado: (2012)

Role of Calcium Gluconate and Iodine in Whooping Cough
por: Misra, R. N.
Publicado: (1941)

Compartment Syndrome Secondary to Calcium Gluconate Extravasation
por: Weimer, Derek S, et al.
Publicado: (2023)

Letrozole and Ovarian Hyperstimulation Syndrome (OHSS): A Promising Prevention Strategy
por: Di Guardo, Federica, et al.
Publicado: (2023)

Ultrastructural characteristics of fibrin clots from canine and feline platelet concentrates activated with calcium gluconate or calcium gluconate plus batroxobin
por: Silva, Raúl F, et al.
Publicado: (2013)

The effect of luteinizing hormone changes in GnRH antagonist protocol on the outcome of controlled ovarian hyperstimulation and embryo transfer
por: Zhou, Jing-Shuang, et al.
Publicado: (2023)

Ovarian Hyperstimulation Syndrome: Current Views on Pathophysiology, Risk Factors, Prevention, and Management
por: Alper, Michael M, et al.
Publicado: (2009)

Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment
por: Fiedler, Klaus, et al.
Publicado: (2012)

Comparison of GnRH Agonist, GnRH Antagonist, and GnRH Antagonist Mild Protocol of Controlled Ovarian Hyperstimulation in Good Prognosis Patients
por: Stimpfel, Martin, et al.
Publicado: (2015)

Ovarian Hyperstimulation Syndrome as an Etiology of Obstructive Uropathy
por: Marak, Creticus P., et al.
Publicado: (2013)

Radiological Illustration of Spontaneous Ovarian Hyperstimulation Syndrome
por: Mittal, Kartik, et al.
Publicado: (2015)

Zika virus during controlled ovarian hyperstimulation
por: Joob, Beuy, et al.
Publicado: (2019)

Immunoglobulin Treatment in Severe Ovarian Hyperstimulation Syndrome
por: Gómez, Gemma Grau, et al.
Publicado: (2019)

Calcium Gluconate in Cardiac Failure: Clinical Pharmacology and Therapeutics
por: Rogen, Alfred S.
Publicado: (1940)

Outcomes of assisted reproduction treatment after dopamine agonist -cabergoline- for prevention of ovarian hyper stimulation syndrome
por: Movahedi, Shohreh, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_obeim14qo3dmlps1ko2qpq6h0a